Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tyrosinemia: a review.

P A Russo1, G A Mitchell, R M Tanguay

  • 1Department of Pathology, Children's Hospital of Philadelphia, 324 S. 34th Street, Philadelphia, PA 19104, USA.

Pediatric and Developmental Pathology : the Official Journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
|May 24, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>LPIN1</i> deficiency with severe recurrent rhabdomyolysis and persistent elevation of creatine kinase levels due to chromosome 2 maternal isodisomy.

Molecular genetics and metabolism reports·2017
Same author

Tyrosinemia type II: Mutation update, 11 novel mutations and description of 5 independent subjects with a novel founder mutation.

Clinical genetics·2017
Same author

Diversity of ARSACS mutations in French-Canadians.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2012
Same author

Aberdeen's Medical History.

British medical journal·2010
Same author

Retroperitoneal Effusions in Renal Regions.

British medical journal·2010
Same author

Letters to the editor.

Anesthesia progress·2009
Same journal

Assessing Normal Histologic Patterns in Perinatal Tissue: A Practical Guide.

Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society·2026
Same journal

Perinatal Autopsy Guidance for the General Pathologist.

Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society·2026
Same journal

The Placenta: Identifying Normal.

Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society·2026
Same journal

Ancillary and Advanced Techniques for the Postmortem Examination.

Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society·2026
Same journal

Terminology in Perinatal Pathology.

Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society·2026
Same journal

Founders in Pediatric Pathology.

Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society·2026
See all related articles

Tyrosinemia type I (HT1) is a severe metabolic disorder affecting the liver, kidneys, and nerves. Advances in diagnosis and management, including the drug NTBC, offer hope for patients, while research explores gene therapy and genetic reversion.

Area of Science:

  • Biochemistry
  • Genetics
  • Pediatric Medicine

Background:

  • Tyrosinemia type I (HT1), or hepatorenal tyrosinemia, is a severe inherited metabolic disorder.
  • It primarily affects the liver, kidneys, and peripheral nerves, with significant clinical and pathological manifestations.
  • HT1 is associated with a high incidence of hepatocellular carcinoma due to accumulated metabolite effects.

Purpose of the Study:

  • To review the clinical and pathological spectrum of tyrosinemia type I.
  • To discuss recent advances in diagnosis, management, and treatment modalities for HT1.
  • To highlight unresolved issues and future research directions in HT1.

Main Methods:

  • Literature review of clinical findings, pathological manifestations, and diagnostic advancements in HT1.

Related Experiment Videos

  • Analysis of current medical and surgical management strategies, including liver transplantation.
  • Exploration of novel therapeutic approaches, including pharmacologic agents (NTBC) and gene therapy.

    • Main Results:

    • Refined diagnostic and management strategies have altered the natural course of HT1.
    • Hepatocellular carcinoma is a significant concern in HT1 patients.
    • NTBC shows promise in alleviating disease burden, and gene therapy is being explored in animal models.
    • Spontaneous genetic reversion has been observed in some HT1 livers.

    Conclusions:

    • Despite advances, long-term follow-up of cirrhosis, timing of liver transplantation, and chronic renal disease progression remain critical issues.
    • The introduction of NTBC and advancements in gene therapy offer new hope for managing HT1.
    • Observations of genetic reversion challenge existing paradigms in human genetics and HT1 pathogenesis.